<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749697</url>
  </required_header>
  <id_info>
    <org_study_id>CCR3047</org_study_id>
    <nct_id>NCT00749697</nct_id>
  </id_info>
  <brief_title>Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases</brief_title>
  <official_title>Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to establish a relationship between the administered
      activity of the radioiodine and absorbed dose in the tumor sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid
      cancer to correlate the administered activity to absorbed dose. Patients will receive the
      standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for
      the protocol purpose.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is to correlate the predicted dose from the tracer study with the actual absorbed dose measure on the therapeutic scan</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcomes will be to assess the response at 6 months post therapy in each patient</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Thyroid Carcinoma</condition>
  <condition>Metastatic Sites Lung Bone Nodal</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SPECT scan</intervention_name>
    <description>SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age above 18

          -  histological confirmation of the differentiated thyroid carcinoma available

          -  WHO performance score 0-2

          -  metastatic sites lung and/or bone and/or nodal (radiologically measurable disease &gt; 1
             cm)

          -  life expectancy &gt; 6 months

          -  patient has undergone total/near total thyroidectomy

          -  no past history of sensitivity/reaction to 1311

        Exclusion Criteria:

          -  non iodine concentrating tumours

          -  received chemotherapy or radiotherapy in 6 weeks

          -  pregnant or breast feeding patients

          -  iodine contrast injection in last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Kate Newbold</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Kate Newbold</last_name>
    <phone>020 86613638</phone>
    <email>kate.newbold@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Prasad Dandekar</last_name>
    <phone>020 8661 3454</phone>
    <email>prasad.dandekar@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>Sutton</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Kate Newbold</last_name>
      <phone>0208661 3638</phone>
      <email>kate.newbold@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Dr Prasad Dandekar</last_name>
      <phone>020 86613454</phone>
      <email>prasad.dandekar@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Kate Newbold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>September 8, 2008</last_update_submitted>
  <last_update_submitted_qc>September 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Kate Newbold</name_title>
    <organization>Royal Marsden NHS Foundation Trust</organization>
  </responsible_party>
  <keyword>radioiodine</keyword>
  <keyword>differentiated thyroid cancers</keyword>
  <keyword>dosimetry</keyword>
  <keyword>metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

